Dow Jones
38.225,66 +322,37 (+0,85%) Nasdaq
15.840,96 +235,48 (+1,51%) Nikkei 225
38.236,07 -37,98 (-0,10%) EUR/USD
1,0740 +0,0013 (+0,12%) Bitcoin EUR
55.306,50 +1.951,90 (+3,66%) CMC Crypto 200
1.279,33 +8,58 (+0,68%)
ChemoMetec A/S (0DZ0.L)
- GlobeNewswire
Notification of managers’ transactions
ANNOUNCEMENT NO. 244 14 September 2023 Notification of managers’ transactions ChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in ChemoMetec A/S made by persons discharging managerial responsibilities in ChemoMetec A/S and/or persons closely associated with them. See the transactions of CEO Rasmus Kofoed in the attached PDF document. For further information, please contact: Niels Høy Nielsen, CFOTelephone
- GlobeNewswire
Annual Report 2022/23 - Continued solid earnings, but weaker growth amid challenging market conditions
ANNOUNCEMENT NO. 243 13 September 2023 Annual Report 2022/23 (1 July 2022 - 30 June 2023) Continued solid earnings, but weaker growth amid challenging market conditions ChemoMetec’s revenue for 2022/23 grew by 4% to DKK 442.3 million and operating profit (EBITDA) for 2022/23 was DKK 251.0 million, a 13% increase on 2021/22. In 2022/23, ChemoMetec continued developing the new Xcyto platform and the instruments XcytoMatic 40 and XcytoMatic 30. In addition to the XcytoMatic instruments, we expect t
- GlobeNewswire
Guidance for the 2023/24 financial year
ANNOUNCEMENT NO. 242 13 September 2023 Guidance for the 2023/24 financial year ChemoMetec has today approved the annual report for 2022/23, including the guidance for 2023/24, which is considered inside information. For 2023/24, ChemoMetec expects revenue in the range of DKK 400-435 million (2022/23: DKK 442.3 million) and EBITDA in the range of DKK 200-220 (2022/23: DKK 251.0 million). The annual report for 2022/23, which is released along with this announcement, sets out the underlying assumpt
